Union Pacific on Pace for Largest Percent Decrease Since October 2023 — Data Talk
Union Pacific Corporation (UNP) is currently at $243.98, down $5.27 or 2.11%
--Would be lowest close since Jan. 31, 2024, when it closed at $243.93
--On pace for largest percent decrease since Oct. 18, 2023, when it fell 2.56%
--Currently down three of the past four days
--Currently down two consecutive days; down 2.87% over this period
--Worst two day stretch since the two days ending Sept. 27, 2023, when it fell 2.92%
--Down 3.83% month-to-date
--Down 0.67% year-to-date
--Down 11.82% from its all-time closing high of $276.69 on March 30, 2022
--Up 26.47% from 52 weeks ago (March 16, 2023), when it closed at $192.91
--Down 5.03% from its 52-week closing high of $256.91 on Feb. 23, 2024
--Up 31.37% from its 52-week closing low of $185.72 on March 22, 2023
--Traded as low as $243.60; lowest intraday level since Jan. 30, 2024, when it hit $242.31
--Down 2.27% at today's intraday low; largest intraday percent decrease since Oct. 18, 2023, when it fell as much as 2.78%
All data as of 11:08:32 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 14, 2024 11:27 ET (15:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks